NewcelX Ltd. (NCEL) Stock Score, Valuation & Financial Research

NewcelX Ltd. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for NCEL

NewcelX Ltd. does not currently have a complete Wall Street Score. The stored market price is USD 2.94. These figures are a research snapshot, not a buy or sell recommendation.

What NewcelX Ltd. does

NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

NewcelX is a clinical-stage biotechnology company that generates no revenue from product sales as it is currently in the research and development phase. Its business model relies on securing financing, grants, and potential future licensing or collaboration agreements to fund the development of its stem-cell-derived therapies and small-molecule CNS therapeutics.

Products and services

  • The company develops off-the-shelf, allogeneic cell-based therapies, including its lead program NCEL-101 for Type 1 Diabetes, and small-molecule therapeutics for neurodegenerative diseases.

Brands and product families

  • NCEL-101 — Lead stem cell-derived islet therapy program for Type 1 Diabetes. Source
  • AstroRx — Cell therapy platform technology. Source

Customer types

Clinical trial participants.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party manufacturers for the production of its clinical trial materials; specific supplier names are unnamed. Source

Business relationships and partnerships

  • Eledon Pharmaceuticals — A collaboration for the accelerated development of the company's Type 1 Diabetes treatment program. Source

Business strengths to evaluate

  • Proprietary stem-cell differentiation platform Source

Business risks and research considerations

  • Going concern uncertainty due to limited cash resources Source
  • Clinical development and regulatory approval risks Source

Sources: Company research source · AstroRx · Eledon Pharmaceuticals · Going concern uncertainty due to limited cash resources

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

NCEL financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.94
Market capitalization:
1.32M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -720.1K
Free cash flow:
USD -2.77M
Cash:
USD 710K
Total debt:
USD 392K
EPS:
USD -36.47

What stands out

  • Free cash flow is USD -2.77M, negative for the stored period.
  • The balance sheet shows USD 710K of cash versus USD 392K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 318K using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for NCEL

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can NCEL fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is NCEL likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for NCEL to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of NCEL's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-08.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research NCEL

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.